FDA Plans Guidance This Year On Co-Development Of Diagnostics And Drugs
This article was originally published in The Gray Sheet
Executive Summary
FDA expects to complete a guidance document on co-development of diagnostics and drugs used for personalized medicine by the end of this year, FDA Commissioner Margaret Hamburg said at a meeting in Washington, D.C., Feb. 25